SLN
OTC MARKETS · Biotechnology

Silence Therapeutics PLC

Small-Cap Stocks Biotech Stocks Healthcare Stocks
$13.97
+0.39 (+2.87%)
As of Aug 15, 1:54 AM ET ·
SLN News1 articles
Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran
Silence Therapeutics (SLN) surged 25%+ as Phase 2 data validated 12-week dosing for divesiran in polycythemia vera, with 88% response rate versus 19% placebo.
Markets